Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
san diego blog main
4
×
clinical trials
san diego top stories
boston
boston blog main
boston top stories
dyne therapeutics
fda
myotonic dystrophy type 1
new york blog main
rare disease drugs
san diego
abide therapeutics
achaogen
adams street partners
allergan
amylin pharmaceuticals
antibiotics
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
ben cravatt
beta lactamase inhibitor
biomedical advanced research and development authority (barda)
biotech ipos
bluebird bio
botox
bristol-myers squibb
deals
drug resistance
drugs
duchenne muscular dystrophy
epilepsy
executives
facioscapulohumeral muscular dystrophy
gabapentin
What
medicines
4
×
therapeutics
4
×
drug
company
developing
diseases
dyne
genetic
ipo
muscle
rare
abide
ago
appointed
bacteria
biopharma
biotechs
brings
business
chief
considering
data
disease
disorders
dyne’s
early
executive
exited
expected
experimental
eyes
fighting
finney
having
humans
infections
infectious
ipos
kevin
launches
Language
unset
Current search:
medicines
×
therapeutics
×
" san diego blog main "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
Former Zavante Executive Tapped as Abide Therapeutics President
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
